statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

An announcement from NewAmsterdam Pharma Company (NAMS) is now available. NewAmsterdam Pharma Company N.V. has announced Juliette Audet's new role...

NewAmsterdam Pharma Announces Executive Leadership Changes

NAARDEN, the Netherlands and MIAMI, April 01, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...

NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer

NewAmsterdam Pharma (NASDAQ:NAMS  Get Free Report) saw an uptick in trading volume on Tuesday . 195,163 shares changed hands during mid-day trading, a decline of 19% from the previous...

NewAmsterdam Pharma (NASDAQ:NAMS) Sees Strong Trading Volume

NAARDEN, the Netherlands and MIAMI, March 25, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...

NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress

Shares of NewAmsterdam Pharma (NASDAQ:NAMS  Get Free Report) have been given a consensus rating of Buy by the six research firms that are covering the company, MarketBeat.com...

NewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Recommendation of "Buy" from Analysts

-- TANDEM is designed to evaluate obicetrapib and ezetimibe fixed-dose combination ( FDC ) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients with HeFH, ASCVD or ASCVD...

NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD

NewAmsterdam Pharma (NASDAQ:NAMS  Free Report) had its price target raised by Royal Bank of Canada from $25.00 to $31.00 in a report published on Thursday, Benzinga reports. They currently...

NewAmsterdam Pharma (NASDAQ:NAMS) PT Raised to $31.00 at Royal Bank of Canada

-- On-track to report topline data from Phase 3 BROOKLYN trial in HeFH in 3Q 2024 and Phase 3 BROADWAY trial in ASCVD in 4Q 2024 -- -- Plan to initiate TANDEM, pivotal Phase 3 trial evaluating...

NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update

NAARDEN, The Netherlands and MIAMI, Feb. 26, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or NewAmsterdam or the Company ), a late-stage, clinical biopharmaceutical...

NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March

Wolverine Asset Management LLC bought a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS  Free Report) in the third quarter, Holdings Channel reports. The fund bought 2,925 shares of...

Wolverine Asset Management LLC Purchases Shares of 2,925 NewAmsterdam Pharma (NASDAQ:NAMS)

NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands.

Watchers	166
52-Wk Low	$5.63
52-Wk High	$26.35

Volume	4,914.00
52-Wk High	$26.35
52-Wk Low	$5.63

NAMS NewAmsterdam Pharma Company NV

About

Feed

News

Sentiment

Fundamentals